No abstract available
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / radiotherapy
-
Adenocarcinoma / secondary
-
Adenocarcinoma / surgery
-
Adenocarcinoma / therapy*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Squamous Cell / drug therapy
-
Carcinoma, Squamous Cell / mortality
-
Carcinoma, Squamous Cell / radiotherapy
-
Carcinoma, Squamous Cell / secondary
-
Carcinoma, Squamous Cell / surgery
-
Carcinoma, Squamous Cell / therapy*
-
Chemotherapy, Adjuvant
-
Disease-Free Survival
-
Esophageal Neoplasms / drug therapy
-
Esophageal Neoplasms / mortality
-
Esophageal Neoplasms / radiotherapy
-
Esophageal Neoplasms / secondary
-
Esophageal Neoplasms / surgery
-
Esophageal Neoplasms / therapy*
-
Esophagectomy* / adverse effects
-
Esophagectomy* / mortality
-
Humans
-
Lymph Node Excision
-
Lymphatic Metastasis
-
Neoadjuvant Therapy
-
Neoplasm Invasiveness
-
Neoplasm Staging
-
Neoplasm, Residual
-
Patient Selection*
-
Radiotherapy, Adjuvant
-
Time Factors
-
Treatment Outcome